Literature DB >> 11064441

Enhanced magnetic resonance imaging in multiple sclerosis.

M Filippi1.   

Abstract

Gadolinium-enhanced magnetic resonance imaging (MRI) is very sensitive in the detection of active lesions of multiple sclerosis (MS) and has become a valuable tool to monitor the evolution of the disease either natural or modified by treatment. In the past few years, several studies, on the one hand, have assessed several ways to increase the sensitivity of enhanced MRI to disease activity and, on the other, have investigated in vivo the nature and evolution of enhancing lesions using different non-conventional MR techniques to better define the relationship between enhancement and tissue loss in MS. The present review is a summary of these studies whose results are discussed in the context of MS clinical trial planning and monitoring. Multiple Sclerosis (2000) 6 320 - 326

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11064441     DOI: 10.1177/135245850000600505

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  13 in total

1.  Modeling MR imaging enhancing-lesion volumes in multiple sclerosis: application in clinical trials.

Authors:  I J van den Elskamp; D L Knol; B M J Uitdehaag; F Barkhof
Journal:  AJNR Am J Neuroradiol       Date:  2011-11-03       Impact factor: 3.825

2.  Cerebral lesions of multiple sclerosis: is gadolinium always irreplaceable in assessing lesion activity?

Authors:  Constantina Andrada Treabă; Rodica Bălaşa; Daniela Maria Podeanu; Iunius Paul Simu; Mircea Marian Buruian
Journal:  Diagn Interv Radiol       Date:  2014 Mar-Apr       Impact factor: 2.630

3.  Magnetic resonance monitoring of lesion evolution in multiple sclerosis.

Authors:  Alex Rovira; Cristina Auger; Juli Alonso
Journal:  Ther Adv Neurol Disord       Date:  2013-09       Impact factor: 6.570

4.  Supervised automatic procedure to identify new lesions in brain MR longitudinal studies of patients with multiple sclerosis.

Authors:  R C Parodi; F Levrero; M P Sormani; A Pilot; G L Mancardi; A Aliprandi; F Sardanelli
Journal:  Radiol Med       Date:  2008-04-02       Impact factor: 3.469

5.  Comparison between gadolinium-enhanced 2D T1-weighted gradient-echo and spin-echo sequences in the detection of active multiple sclerosis lesions on 3.0T MRI.

Authors:  F X Aymerich; C Auger; P Alcaide-Leon; D Pareto; E Huerga; J F Corral; R Mitjana; J Sastre-Garriga; X Montalban; A Rovira
Journal:  Eur Radiol       Date:  2016-07-25       Impact factor: 5.315

6.  Evolution of the blood-brain barrier in newly forming multiple sclerosis lesions.

Authors:  María I Gaitán; Colin D Shea; Iordanis E Evangelou; Roger D Stone; Kaylan M Fenton; Bibiana Bielekova; Luca Massacesi; Daniel S Reich
Journal:  Ann Neurol       Date:  2011-06-27       Impact factor: 10.422

Review 7.  Quantification and clinical relevance of brain atrophy in multiple sclerosis: a review.

Authors:  Blandine Grassiot; Béatrice Desgranges; Francis Eustache; Gilles Defer
Journal:  J Neurol       Date:  2009-04-08       Impact factor: 4.849

Review 8.  The place of conventional MRI and newly emerging MRI techniques in monitoring different aspects of treatment outcome.

Authors:  Robert Zivadinov; Milena Stosic; Jennifer L Cox; Deepa P Ramasamy; Michael G Dwyer
Journal:  J Neurol       Date:  2008-03       Impact factor: 4.849

9.  The value of chemical fat-saturation pulse added to T1-weighted spin-echo sequence in evaluating gadolinium-enhancing brain lesions in multiple sclerosis.

Authors:  F Sardanelli; S Schiavoni; A Iozzelli; A Fausto; A Aliprandi; G L Mancardi; M Filippi
Journal:  Radiol Med       Date:  2007-12-13       Impact factor: 3.469

10.  Comparing MRI metrics to quantify white matter microstructural damage in multiple sclerosis.

Authors:  Ilona Lipp; Derek K Jones; Sonya Bells; Eleonora Sgarlata; Catherine Foster; Rachael Stickland; Alison E Davidson; Emma C Tallantyre; Neil P Robertson; Richard G Wise; Valentina Tomassini
Journal:  Hum Brain Mapp       Date:  2019-03-19       Impact factor: 5.038

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.